Apellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Neutral at The Goldman Sachs Group

Apellis Pharmaceuticals (NASDAQ:APLS) was downgraded by investment analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a research report issued on Tuesday, MarketBeat Ratings reports. They presently have a $36.00 price objective on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 5.82% from the company’s current price.

APLS has been the topic of several other reports. William Blair started coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Oppenheimer decreased their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Bank of America dropped their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Mizuho decreased their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Finally, HC Wainwright cut their price target on shares of Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ:APLS opened at $34.02 on Tuesday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock’s 50-day moving average is $29.92 and its 200-day moving average is $34.64. The company has a market cap of $4.23 billion, a P/E ratio of -16.76 and a beta of 0.94. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.17) earnings per share. Equities research analysts predict that Apellis Pharmaceuticals will post -1.72 earnings per share for the current year.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at approximately $27,000. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at approximately $27,000. Capital Performance Advisors LLP bought a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $56,000. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the last quarter. Finally, nVerses Capital LLC grew its holdings in Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).